This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Akinaga, S. Articles by Okabe, M. Search for Related Content PubMed PubMed Citation Articles by Akinaga, S. Articles by Okabe, M.

Antitumor Activity of UCN-01, a Selective Inhibitor of Protein Kinase C, in Murine and Human Tumor Models

Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Shimotogari 1188, Nagaizumi-cho, Sunto-gun, Shizuoka-ken 411 [S. A., K. G., M. M., M. O.], and Tokyo Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Asahimachi 3-6-6, Machida-shi, Tokyo 194 [T. T.], Japan

Antitumor activity of UCN-01 (7-hydroxy staurosporine), a selective inhibitor of Ca²⁺- and phospholipid-dependent protein kinase C, was examined in comparison with staurosporine, a nonselective inhibitor of protein kinases, on human and murine tumor cell lines which have some aberrations in cellular signal transduction. UCN-01 inhibited the growth of five tumor cell lines about 9 to 90 times less potently than staurosporine in vitro. UCN-01 showed an in vivo antitumor effect against three human tumor xenografts [epidermoid carcinoma A431 (c-erbB-1 overexpression), fibrosarcoma HT1080 (N-ras activation), and acute myeloid leukemia HL-60 (N-ras activation)], giving a minimum treated/control ratio of 0.40 (P < 0.01), 0.17 (P < 0.01), and 0.61 (P < 0.05), respectively. UCN-01 also exhibited significant antitumor activity against two murine tumor models (fibrosarcoma, K-BALB and M-MSV-BALB), which activated the v-ras and v-mos oncogenes, showing a minimum treated/control ratio of 0.27 (P < 0.01) and 0.21 (P < 0.01). Staurosporine did not show significant antitumor activity against any of these five tumors. UCN-01 inhibited the down-modulation of epidermal growth factor receptor caused by phorbol 12-myristate 13-acetate in A431 cells at a near 50% inhibitory concentration for cell growth. These results imply that UCN-01 is a promising antitumor agent which has a novel mechanism(s) of action.

¹ To whom requests for reprints should be addressed.

Received 3/18/91. Accepted 7/ 8/91.

This article has been cited by other articles:

				M. B. Thomas and J. L. Abbruzzese Opportunities for Targeted Therapies in Hepatocellular Carcinoma J. Clin. Oncol., November 1, 2005; 23(31): 8093 - 8108. [Abstract] [Full Text] [PDF]

				P. N. Lara Jr, P. C. Mack, T. Synold, P. Frankel, J. Longmate, P. H. Gumerlock, J. H. Doroshow, and D. R. Gandara The Cyclin-Dependent Kinase Inhibitor UCN-01 Plus Cisplatin in Advanced Solid Tumors: A California Cancer Consortium Phase I Pharmacokinetic and Molecular Correlative Trial Clin. Cancer Res., June 15, 2005; 11(12): 4444 - 4450. [Abstract] [Full Text] [PDF]

				X.-Y. Pei, Y. Dai, M. Rahmani, W. Li, P. Dent, and S. Grant The Farnesyltransferase Inhibitor L744832 Potentiates UCN-01-Induced Apoptosis in Human Multiple Myeloma Cells Clin. Cancer Res., June 15, 2005; 11(12): 4589 - 4600. [Abstract] [Full Text] [PDF]

				E. Fuse, T. Kuwabara, A. Sparreboom, E. A. Sausville, and W. D. Figg Review of UCN-01 Development: A Lesson in the Importance of Clinical Pharmacology J. Clin. Pharmacol., April 1, 2005; 45(4): 394 - 403. [Abstract] [Full Text] [PDF]

				J. Kortmansky, M. A. Shah, A. Kaubisch, A. Weyerbacher, S. Yi, W. Tong, R. Sowers, M. Gonen, E. O'Reilly, N. Kemeny, et al. Phase I Trial of the Cyclin-Dependent Kinase Inhibitor and Protein Kinase C Inhibitor 7-Hydroxystaurosporine in Combination With Fluorouracil in Patients With Advanced Solid Tumors J. Clin. Oncol., March 20, 2005; 23(9): 1875 - 1884. [Abstract] [Full Text] [PDF]

				M. Hahn, W. Li, C. Yu, M. Rahmani, P. Dent, and S. Grant Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways Mol. Cancer Ther., March 1, 2005; 4(3): 457 - 470. [Abstract] [Full Text] [PDF]

				E. C. Dees, S. D. Baker, S. O'Reilly, M. A. Rudek, S. B. Davidson, C. Aylesworth, K. Elza-Brown, M. A. Carducci, and R. C. Donehower A Phase I and Pharmacokinetic Study of Short Infusions of UCN-01 in Patients with Refractory Solid Tumors Clin. Cancer Res., January 15, 2005; 11(2): 664 - 671. [Abstract] [Full Text] [PDF]

				M. Katsuki, V. T. G. Chuang, K. Nishi, K. Kawahara, H. Nakayama, N. Yamaotsu, S. Hirono, and M. Otagiri Use of Photoaffinity Labeling and Site-directed Mutagenesis for Identification of the Key Residue Responsible for Extraordinarily High Affinity Binding of UCN-01 in Human {alpha}1-Acid Glycoprotein J. Biol. Chem., January 14, 2005; 280(2): 1384 - 1391. [Abstract] [Full Text] [PDF]

				X. Jiang, B. Zhao, R. Britton, L. Y. Lim, D. Leong, J. S. Sanghera, B.-B. S. Zhou, E. Piers, R. J. Andersen, and M. Roberge Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide Mol. Cancer Ther., October 1, 2004; 3(10): 1221 - 1227. [Abstract] [Full Text] [PDF]

				G. P. Dasmahapatra, P. Didolkar, M. C. Alley, S. Ghosh, E. A. Sausville, and K. K. Roy In vitro Combination Treatment with Perifosine and UCN-01 Demonstrates Synergism against Prostate (PC-3) and Lung (A549) Epithelial Adenocarcinoma Cell Lines Clin. Cancer Res., August 1, 2004; 10(15): 5242 - 5252. [Abstract] [Full Text] [PDF]

				S. Grant and P. Dent Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: What's in a name? Mol. Cancer Ther., July 1, 2004; 3(7): 873 - 875. [Full Text] [PDF]

				P. Amornphimoltham, V. Sriuranpong, V. Patel, F. Benavides, C. J. Conti, J. Sauk, E. A. Sausville, A. A. Molinolo, and J. S. Gutkind Persistent Activation of the Akt Pathway in Head and Neck Squamous Cell Carcinoma: A Potential Target for UCN-01 Clin. Cancer Res., June 15, 2004; 10(12): 4029 - 4037. [Abstract] [Full Text] [PDF]

				M. M. Facchinetti, A. De Siervi, D. Toskos, and A. M. Senderowicz UCN-01-Induced Cell Cycle Arrest Requires the Transcriptional Induction of p21waf1/cip1 by Activation of Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase/Extracellular Signal-Regulated Kinase Pathway Cancer Res., May 15, 2004; 64(10): 3629 - 3637. [Abstract] [Full Text] [PDF]

				W. Jia, C. Yu, M. Rahmani, G. Krystal, E. A. Sausville, P. Dent, and S. Grant Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways Blood, September 1, 2003; 102(5): 1824 - 1832. [Abstract] [Full Text] [PDF]

				V. Patel, T. Lahusen, C. Leethanakul, T. Igishi, M. Kremer, L. Quintanilla-Martinez, J. F. Ensley, E. A. Sausville, J. S. Gutkind, and A. M. Senderowicz Antitumor Activity of UCN-01 in Carcinomas of the Head and Neck Is Associated with Altered Expression of Cyclin D3 and p27KIP1 Clin. Cancer Res., November 1, 2002; 8(11): 3549 - 3560. [Abstract] [Full Text] [PDF]

				C. Carrasco, M. Facompre, J. D. Chisholm, D. L. Van Vranken, W. D. Wilson, and C. Bailly DNA sequence recognition by the indolocarbazole antitumor antibiotic AT2433-B1 and its diastereoisomer Nucleic Acids Res., April 15, 2002; 30(8): 1774 - 1781. [Abstract] [Full Text] [PDF]

				A. B. da Rocha, D.R.A. Mans, A. Regner, and G. Schwartsmann Targeting Protein Kinase C: New Therapeutic Opportunities Against High-Grade Malignant Gliomas? Oncologist, February 1, 2002; 7(1): 17 - 33. [Abstract] [Full Text] [PDF]

				Y. A. Elsayed and E. A. Sausville Selected Novel Anticancer Treatments Targeting Cell Signaling Proteins Oncologist, December 1, 2001; 6(6): 517 - 537. [Abstract] [Full Text] [PDF]

				E. A. Kruger and W. D. Figg Protein Binding Alters the Activity of Suramin, Carboxyamidotriazole, and UCN-01 in an ex Vivo Rat Aortic Ring Angiogenesis Assay Clin. Cancer Res., July 1, 2001; 7(7): 1867 - 1872. [Abstract] [Full Text] [PDF]

				M. V. Blagosklonny and A. B. Pardee Exploiting Cancer Cell Cycling for Selective Protection of Normal Cells Cancer Res., June 1, 2001; 61(11): 4301 - 4305. [Abstract] [Full Text] [PDF]

				E. A. Sausville, S. G. Arbuck, R. Messmann, D. Headlee, K. S. Bauer, R. M. Lush, A. Murgo, W. D. Figg, T. Lahusen, S. Jaken, et al. Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms J. Clin. Oncol., April 15, 2001; 19(8): 2319 - 2333. [Abstract] [Full Text] [PDF]

				S. D. Mertins, T. G. Myers, M. Hollingshead, D. Dykes, E. Bodde, P. Tsai, C. A. Jefferis, R. Gupta, W. M. Linehan, M. Alley, et al. Screening for and Identification of Novel Agents Directed at Renal Cell Carcinoma Clin. Cancer Res., March 1, 2001; 7(3): 620 - 633. [Abstract] [Full Text]

				Z. Shi, A. Azuma, D. Sampath, Y.-X. Li, P. Huang, and W. Plunkett S-Phase Arrest by Nucleoside Analogues and Abrogation of Survival without Cell Cycle Progression by 7-Hydroxystaurosporine Cancer Res., February 1, 2001; 61(3): 1065 - 1072. [Abstract] [Full Text]

				S. Harvey, R. Decker, Y. Dai, G. Schaefer, L. Tang, L. Kramer, P. Dent, and S. Grant Interactions between 2-Fluoroadenine 9-{beta}-D-Arabinofuranoside and the Kinase Inhibitor UCN-01 in Human Leukemia and Lymphoma Cells Clin. Cancer Res., February 1, 2001; 7(2): 320 - 330. [Abstract] [Full Text]

				M. Omura-Minamisawa, M. B. Diccianni, A. Batova, R. C. Chang, L. J. Bridgeman, J. Yu, Esther de Wit, F. H. Kung, J. D. Pullen, and A. L. Yu In Vitro Sensitivity of T-Cell Lymphoblastic Leukemia to UCN-01 (7-Hydroxystaurosporine) Is Dependent on p16 Protein Status: A Pediatric Oncology Group Study Cancer Res., December 1, 2000; 60(23): 6573 - 6576. [Abstract] [Full Text]

				A. M. Senderowicz and E. A. Sausville RESPONSE: Re: Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators J Natl Cancer Inst, July 19, 2000; 92(14): 1185 - 1185. [Full Text] [PDF]

				A. M. Senderowicz and E. A. Sausville Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators J Natl Cancer Inst, March 1, 2000; 92(5): 376 - 387. [Abstract] [Full Text] [PDF]

				W. H. Wilson, L. Sorbara, W. D. Figg, E. K. Mont, E. Sausville, K. E. Warren, F. M. Balis, K. Bauer, M. Raffeld, A. M. Senderowicz, et al. Modulation of Clinical Drug Resistance in a B Cell Lymphoma Patient by the Protein Kinase Inhibitor 7-Hydroxystaurosporine: Presentation of a Novel Therapeutic Paradigm Clin. Cancer Res., February 1, 2000; 6(2): 415 - 421. [Abstract] [Full Text]

				K. Sugiyama, T. Akiyama, M. Shimizu, T. Tamaoki, C. Courage, A. Gescher, and S. Akinaga Decrease in Susceptibility Toward Induction of Apoptosis and Alteration in G1 Checkpoint Function as Determinants of Resistance of Human Lung Cancer Cells against the Antisignaling Drug UCN-01 (7-Hydroxystaurosporine) Cancer Res., September 1, 1999; 59(17): 4406 - 4412. [Abstract] [Full Text] [PDF]

				P. C. Mack, D. R. Gandara, C. Bowen, M. J. Edelman, T. Paglieroni, J. B. Schnier, E. P. Gelmann, and P. H. Gumerlock RB Status as a Determinant of Response to UCN-01 in Non-Small Cell Lung Carcinoma Clin. Cancer Res., September 1, 1999; 5(9): 2596 - 2604. [Abstract] [Full Text] [PDF]

				E. Fuse, H. Tanii, K. Takai, K. Asanome, N. Kurata, H. Kobayashi, T. Kuwabara, S. Kobayashi, and Y. Sugiyama Altered Pharmacokinetics of a Novel Anticancer Drug, UCN-01, Caused by Specific High Affinity Binding to {{alpha}}1-Acid Glycoprotein in Humans Cancer Res., March 1, 1999; 59(5): 1054 - 1060. [Abstract] [Full Text] [PDF]

				C. Bailly, X. Qu, F. Anizon, M. Prudhomme, J.-F. Riou, and J. B. Chaires Enhanced Binding to DNA and Topoisomerase I Inhibition by an Analog of the Antitumor Antibiotic Rebeccamycin Containing an Amino Sugar Residue Mol. Pharmacol., February 1, 1999; 55(2): 377 - 385. [Abstract] [Full Text]

				L. Yu, L. Orlandi, P. Wang, M. S. Orr, A. M. Senderowicz, E. A. Sausville, R. Silvestrini, N. Watanabe, H. Piwnica-Worms, and P. M. O'Connor UCN-01 Abrogates G2 Arrest through a Cdc2-dependent Pathway That Is Associated with Inactivation of the Wee1Hu Kinase and Activation of the Cdc25C Phosphatase J. Biol. Chem., December 11, 1998; 273(50): 33455 - 33464. [Abstract] [Full Text] [PDF]

				S. T. Harkin, G. M. Cohen, and A. Gescher Modulation of Apoptosis in Rat Thymocytes by Analogs of Staurosporine: Lack of Direct Association with Inhibition of Protein Kinase C Mol. Pharmacol., October 1, 1998; 54(4): 663 - 670. [Abstract] [Full Text]

				R.-G. Shao, C.-X. Cao, and Y. Pommier Activation of PKCalpha Downstream from Caspases during Apoptosis Induced by 7-Hydroxystaurosporine or the Topoisomerase Inhibitors, Camptothecin and Etoposide, in Human Myeloid Leukemia HL60 Cells J. Biol. Chem., December 12, 1997; 272(50): 31321 - 31325. [Abstract] [Full Text] [PDF]

				T. Murohara, R. Scalia, and A. M. Lefer Lysophosphatidylcholine Promotes P-Selectin Expression in Platelets and Endothelial Cells : Possible Involvement of Protein Kinase C Activation and Its Inhibition by Nitric Oxide Donors Circ. Res., May 1, 1996; 78(5): 780 - 789. [Abstract] [Full Text]

				T. Murohara, S. J. Parkinson, S. A. Waldman, and A. M. Lefer Inhibition of Nitric Oxide Biosynthesis Promotes P-selectin Expression in Platelets : Role of Protein Kinase C Arterioscler. Thromb. Vasc. Biol., November 1, 1995; 15(11): 2068 - 2075. [Abstract] [Full Text]

				D. Curman, B. Cinel, D. E. Williams, N. Rundle, W. D. Block, A. A. Goodarzi, J. R. Hutchins, P. R. Clarke, B.-B. Zhou, S. P. Lees-Miller, et al. Inhibition of the G2 DNA Damage Checkpoint and of Protein Kinases Chk1 and Chk2 by the Marine Sponge Alkaloid Debromohymenialdisine J. Biol. Chem., May 18, 2001; 276(21): 17914 - 17919. [Abstract] [Full Text] [PDF]